Details of the Drug

General Information of Drug (ID: DM9OZWQ)

Drug Name
Lovastatin
Synonyms
lovastatin; 75330-75-5; mevinolin; Mevacor; Lovalip; Monacolin K; Lovalord; Mevinacor; Altoprev; Nergadan; Artein; Altocor; 6alpha-Methylcompactin; MK-803; Hipovastin; Lovastatine; Lovasterol; Paschol; Lipivas; Closterol; Teroltrat; Tecnolip; Rovacor; Cholestra; Rodatin; Lozutin; Lipofren; Lestatin; Hipolip; Colevix; Sivlor; Taucor; Lipdip; Belvas; Mevlor; Lovastatine [French]; Lovastatinum [Latin]; Lovastatina [Spanish]; 6-alpha-Methylcompactin; Lovastatinum; Lovastatina; Lovastin; MSD 803; MK 803; 6 alpha-Methylcompactin; UNII-9LHU78OQFD; Altocor; Liposcler; Mevinolin; Rextat; Sivlor;Taucor; Monakolin K; MK803; Advicor (TN); Altocor (TN); Altoprev (TN); L-154803; Lovastatin & Primycin; ML-530B; Mevacor (TN); Mevinolin from Aspergillus sp; Statosan (TN); Lovastatin (USP/INN); Lovastatin [USAN:BAN:INN]; Lovastatin, (1 alpha(S*))-Isomer; Lovastatin, 1 alpha-Isomer (without R*/S* notation); 2beta,6alpha-Dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone; 6 Methylcompactin; 6-Methylcompactin; Aspirin/lisinopril/ lovastatin fixed-dose combination
Indication
Disease Entry ICD 11 Status REF
Arteriosclerosis BD40 Approved [1]
Hypercholesterolaemia 5C80.0 Approved [2]
Hyperlipidemia 5C80.Z Approved [1]
Hyperlipidemia, familial combined, LPL related N.A. Approved [1]
Hypertriglyceridemia 5C80.1 Approved [1]
Melanoma 2C30 Approved [1]
X-linked chondrodysplasia punctata 2 N.A. Approved [1]
Cardiovascular disease BA00-BE2Z Phase 3 [3]
Smith-Lemli-Opitz syndrome N.A. Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticholesteremic Agents
Affected Organisms
Humans and other mammals
ATC Code
C10AA02: Lovastatin
C10AA: HMG CoA reductase inhibitors
C10A: LIPID MODIFYING AGENTS, PLAIN
C10: LIPID MODIFYING AGENTS
C: CARDIOVASCULAR SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 404.5
Logarithm of the Partition Coefficient (xlogp) 4.3
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 3.013 mcg/L []
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 3.36 h []
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Elimination
Following an oral dose of 14C-labeled lovastatin to man, 10% of the dose was excreted in urine and 83% in feces []
Half-life
The concentration or amount of drug in body reduced by one-half in 13.37 hours []
Metabolism
The drug is metabolized via serum paraoxonase [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 3.28759 micromolar/kg/day [6]
Water Solubility
The ability of drug to dissolve in water is measured as 0.0004 mg/mL [4]
Chemical Identifiers
Formula
C24H36O5
IUPAC Name
[(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate
Canonical SMILES
CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C
InChI
InChI=1S/C24H36O5/c1-5-15(3)24(27)29-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-19-12-18(25)13-22(26)28-19/h6-7,10,14-16,18-21,23,25H,5,8-9,11-13H2,1-4H3/t14-,15-,16-,18+,19+,20-,21-,23-/m0/s1
InChIKey
PCZOHLXUXFIOCF-BXMDZJJMSA-N
Cross-matching ID
PubChem CID
53232
ChEBI ID
CHEMBL503
CAS Number
75330-75-5
UNII
9LHU78OQFD
DrugBank ID
DB00227
TTD ID
D06WTZ
VARIDT ID
DR00410
INTEDE ID
DR0986
ACDINA ID
D00377
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug Pharmacogenomic Perturbation (DPP)NEW Click to Jump to the Detailed DPP Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
HMG-CoA reductase (HMGCR) TTPADOQ HMDH_HUMAN Inhibitor [7]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [8]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [10]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [11]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [11]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [11]
UDP-glucuronosyltransferase 2B7 (UGT2B7) DEB3CV1 UD2B7_HUMAN Substrate [11]
UDP-glucuronosyltransferase 1A3 (UGT1A3) DEF2WXN UD13_HUMAN Substrate [11]
Serum paraoxonase/lactonase 3 (PON3) DETXQZ1 PON3_HUMAN Substrate [12]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
A-kinase anchor protein 7 isoforms alpha and beta (AKAP7) OT0L3PZ6 AKA7A_HUMAN Drug Response [13]
Actin, aortic smooth muscle (ACTA2) OTEDLG8E ACTA_HUMAN Gene/Protein Processing [14]
Amyloid-beta precursor protein (APP) OTKFD7R4 A4_HUMAN Protein Interaction/Cellular Processes [15]
Ankyrin-2 (ANK2) OTWB4R1Y ANK2_HUMAN Drug Response [13]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Regulation of Drug Effects [16]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Gene/Protein Processing [17]
Bcl-2-like protein 11 (BCL2L11) OTNQQWFJ B2L11_HUMAN Gene/Protein Processing [18]
Beta-parvin (PARVB) OT9OGVWX PARVB_HUMAN Drug Response [13]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Gene/Protein Processing [19]
CD44 antigen (CD44) OT9TTJ41 CD44_HUMAN Gene/Protein Processing [20]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Arteriosclerosis
ICD Disease Classification BD40
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
HMG-CoA reductase (HMGCR) DTT HMGCR 1.01E-05 0.65 1.53
P-glycoprotein 1 (ABCB1) DTP P-GP 3.29E-14 -7.08E-01 -1.99E+00
Organic anion transporting polypeptide 1B1 (SLCO1B1) DTP OATP1B1 3.27E-01 -5.78E-02 -3.84E-01
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME UGT1A1 2.00E-01 5.79E-02 3.00E-01
Serum paraoxonase/lactonase 3 (PON3) DME PON3 2.30E-02 -3.44E-01 -1.20E+00
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 1.47E-02 -1.13E-01 -1.13E+00
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 4.03E-02 -1.19E-01 -5.11E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 3.24E-05 -3.48E-01 -1.34E+00
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Lovastatin
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Bempedoic acid DM1CI9R Moderate Decreased clearance of Lovastatin due to the transporter inhibition by Bempedoic acid. Hyper-lipoproteinaemia [5C80] [21]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Lovastatin and Mipomersen. Hyper-lipoproteinaemia [5C80] [22]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Lovastatin and Teriflunomide. Hyper-lipoproteinaemia [5C80] [23]
BMS-201038 DMQTAGO Major Decreased metabolism of Lovastatin caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [24]
Coadministration of a Drug Treating the Disease Different from Lovastatin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Lovastatin and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [25]
Thioguanine DM7NKEV Moderate Increased risk of hepatotoxicity by the combination of Lovastatin and Thioguanine. Acute myeloid leukaemia [2A60] [26]
Ivosidenib DM8S6T7 Moderate Increased metabolism of Lovastatin caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [27]
Midostaurin DMI6E0R Moderate Decreased clearance of Lovastatin due to the transporter inhibition by Midostaurin. Acute myeloid leukaemia [2A60] [28]
Idarubicin DMM0XGL Moderate Decreased clearance of Lovastatin due to the transporter inhibition by Idarubicin. Acute myeloid leukaemia [2A60] [29]
Daunorubicin DMQUSBT Moderate Decreased clearance of Lovastatin due to the transporter inhibition by Daunorubicin. Acute myeloid leukaemia [2A60] [29]
Arn-509 DMT81LZ Moderate Increased metabolism of Lovastatin caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [28]
Emapalumab DMZG5WL Moderate Altered metabolism of Lovastatin due to Emapalumab alters the formation of CYP450 enzymes. Adaptive immunity immunodeficiency [4A01] [28]
Siltuximab DMGEATB Moderate Altered metabolism of Lovastatin due to Siltuximab alters the formation of CYP450 enzymes. Anemia [3A00-3A9Z] [28]
Ranolazine DM0C9IL Major Decreased metabolism of Lovastatin caused by Ranolazine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [28]
Dronedarone DMA8FS5 Major Decreased metabolism of Lovastatin caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [30]
Nifedipine DMSVOZT Moderate Decreased metabolism of Lovastatin caused by Nifedipine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [31]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Lovastatin and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [32]
Voriconazole DMAOL2S Major Decreased metabolism of Lovastatin caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [33]
Posaconazole DMUL5EW Major Decreased metabolism of Lovastatin caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [25]
Ciprofloxacin XR DM2NLS9 Moderate Decreased metabolism of Lovastatin caused by Ciprofloxacin XR mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [31]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Lovastatin caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [34]
Clarithromycin DM4M1SG Major Decreased metabolism of Lovastatin caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [33]
Telithromycin DMZ4P3A Major Decreased metabolism of Lovastatin caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [35]
Ag-221 DMS0ZBI Moderate Decreased clearance of Lovastatin due to the transporter inhibition by Ag-221. BCR-ABL1-negative chronic myeloid leukaemia [2A41] [25]
Erdafitinib DMI782S Moderate Increased metabolism of Lovastatin caused by Erdafitinib mediated induction of CYP450 enzyme. Bladder cancer [2C94] [36]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Lovastatin and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [37]
Talazoparib DM1KS78 Moderate Decreased clearance of Lovastatin due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [38]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Lovastatin caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [31]
Tucatinib DMBESUA Major Decreased metabolism of Lovastatin caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [39]
Palbociclib DMD7L94 Moderate Decreased metabolism of Lovastatin caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [31]
Grepafloxacin DMGLX0T Moderate Decreased metabolism of Lovastatin caused by Grepafloxacin mediated inhibition of CYP450 enzyme. Bronchitis [CA20] [31]
Mifepristone DMGZQEF Major Decreased metabolism of Lovastatin caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [40]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Lovastatin caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [31]
Lumacaftor DMCLWDJ Major Increased metabolism of Lovastatin caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [25]
Ivacaftor DMZC1HS Moderate Decreased clearance of Lovastatin due to the transporter inhibition by Ivacaftor. Cystic fibrosis [CA25] [41]
MK-8228 DMOB58Q Major Decreased clearance of Lovastatin due to the transporter inhibition by MK-8228. Cytomegaloviral disease [1D82] [42]
Aprepitant DM053KT Moderate Decreased metabolism of Lovastatin caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [31]
Nefazodone DM4ZS8M Major Decreased metabolism of Lovastatin caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [39]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Lovastatin caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [43]
Stiripentol DMMSDOY Moderate Decreased metabolism of Lovastatin caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [44]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Lovastatin and Cannabidiol. Epileptic encephalopathy [8A62] [28]
Itraconazole DMCR1MV Major Decreased metabolism of Lovastatin caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [23]
Clotrimazole DMMFCIH Moderate Decreased metabolism of Lovastatin caused by Clotrimazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [28]
Miconazole DMPMYE8 Moderate Decreased metabolism of Lovastatin caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [28]
Ketoconazole DMPZI3Q Major Decreased metabolism of Lovastatin caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [45]
Omeprazole DM471KJ Moderate Increased plasma concentrations of Lovastatin and Omeprazole due to competitive inhibition of the same metabolic pathway. Gastro-oesophageal reflux disease [DA22] [46]
Cimetidine DMH61ZB Moderate Decreased metabolism of Lovastatin caused by Cimetidine mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [31]
Boceprevir DMBSHMF Major Decreased metabolism of Lovastatin caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [33]
Simeprevir DMLUA9D Moderate Decreased clearance of Lovastatin due to the transporter inhibition by Simeprevir. Hepatitis virus infection [1E50-1E51] [47]
Telaprevir DMMRV29 Major Decreased metabolism of Lovastatin caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [33]
Rifampin DMA8J1G Major Accelerated clearance of Lovastatin due to the transporter induction by Rifampin. HIV-infected patients with tuberculosis [1B10-1B14] [46]
Rifapentine DMCHV4I Moderate Increased metabolism of Lovastatin caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [48]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Lovastatin and Brentuximab vedotin. Hodgkin lymphoma [2B30] [49]
Delavirdine DM3NF5G Major Decreased metabolism of Lovastatin caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [50]
Fosamprenavir DM4W9B3 Major Decreased metabolism of Lovastatin caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [51]
Fostemsavir DM50ILT Moderate Decreased clearance of Lovastatin due to the transporter inhibition by Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [52]
Nevirapine DM6HX9B Moderate Increased metabolism of Lovastatin caused by Nevirapine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [53]
Cobicistat DM6L4H2 Major Decreased metabolism of Lovastatin caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [39]
Tipranavir DM8HJX6 Major Decreased metabolism of Lovastatin caused by Tipranavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [51]
Efavirenz DMC0GSJ Moderate Increased metabolism of Lovastatin caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [53]
Saquinavir DMG814N Major Decreased metabolism of Lovastatin caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [51]
Etravirine DMGV8QU Moderate Increased metabolism of Lovastatin caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [54]
Zalcitabine DMH7MUV Moderate Increased risk of peripheral neuropathy by the combination of Lovastatin and Zalcitabine. Human immunodeficiency virus disease [1C60-1C62] [55]
Amprenavir DMLMXE0 Major Decreased metabolism of Lovastatin caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [51]
Darunavir DMN3GCH Major Decreased metabolism of Lovastatin caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [51]
Atazanavir DMSYRBX Major Decreased metabolism of Lovastatin caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [51]
Ritonavir DMU764S Major Decreased metabolism of Lovastatin caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [51]
Levamlodipine DM92S6N Moderate Decreased metabolism of Lovastatin caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [31]
Diltiazem DMAI7ZV Major Decreased clearance of Lovastatin due to the transporter inhibition by Diltiazem. Hypertension [BA00-BA04] [31]
Amlodipine DMBDAZV Moderate Decreased metabolism of Lovastatin caused by Amlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [31]
Conivaptan DM1V329 Major Decreased metabolism of Lovastatin caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [33]
Tolvaptan DMIWFRL Minor Decreased metabolism of Lovastatin caused by Tolvaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [56]
Lesinurad DMUR64T Moderate Increased metabolism of Lovastatin caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [57]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Lovastatin caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [31]
Suvorexant DM0E6S3 Moderate Decreased metabolism of Lovastatin caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [31]
Methotrexate DM2TEOL Moderate Increased risk of hepatotoxicity by the combination of Lovastatin and Methotrexate. Leukaemia [2A60-2B33] [28]
Crizotinib DM4F29C Moderate Decreased metabolism of Lovastatin caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [31]
Brigatinib DM7W94S Moderate Increased metabolism of Lovastatin caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [58]
Ceritinib DMB920Z Major Decreased metabolism of Lovastatin caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [39]
PF-06463922 DMKM7EW Moderate Increased metabolism of Lovastatin caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [59]
Osimertinib DMRJLAT Moderate Increased metabolism of Lovastatin caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [28]
Selpercatinib DMZR15V Moderate Decreased metabolism of Lovastatin caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [31]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Lovastatin and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [60]
Idelalisib DM602WT Major Decreased metabolism of Lovastatin caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [39]
IPI-145 DMWA24P Moderate Decreased metabolism of Lovastatin caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [31]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Lovastatin and Clofarabine. Mature B-cell lymphoma [2A85] [61]
Arry-162 DM1P6FR Moderate Decreased clearance of Lovastatin due to the transporter inhibition by Arry-162. Melanoma [2C30] [25]
LGX818 DMNQXV8 Moderate Increased metabolism of Lovastatin caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [62]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Lovastatin caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [25]
Danazol DML8KTN Major Decreased metabolism of Lovastatin caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [34]
Exjade DMHPRWG Moderate Decreased metabolism of Lovastatin caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [63]
Thalidomide DM70BU5 Moderate Increased risk of peripheral neuropathy by the combination of Lovastatin and Thalidomide. Multiple myeloma [2A83] [55]
Bexarotene DMOBIKY Moderate Increased metabolism of Lovastatin caused by Bexarotene mediated induction of CYP450 enzyme. Mycosis fungoides [2B01] [28]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Lovastatin caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [31]
Nilotinib DM7HXWT Moderate Decreased metabolism of Lovastatin caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [31]
Imatinib DM7RJXL Moderate Decreased metabolism of Lovastatin caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [31]
Dasatinib DMJV2EK Moderate Decreased metabolism of Lovastatin caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [31]
Modafinil DMYILBE Moderate Increased metabolism of Lovastatin caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [25]
Netupitant DMEKAYI Moderate Decreased metabolism of Lovastatin caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [34]
Entrectinib DMMPTLH Moderate Decreased metabolism of Lovastatin caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [31]
Olaparib DM8QB1D Moderate Decreased clearance of Lovastatin due to the transporter inhibition by Olaparib. Ovarian cancer [2C73] [25]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Lovastatin caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [31]
Abametapir DM2RX0I Moderate Decreased metabolism of Lovastatin caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [64]
Esomeprazole DM7BN0X Moderate Increased plasma concentrations of Lovastatin and Esomeprazole due to competitive inhibition of the same metabolic pathway. Peptic ulcer [DA61] [46]
Lefamulin DME6G97 Moderate Decreased metabolism of Lovastatin caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [65]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Lovastatin caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [66]
Enzalutamide DMGL19D Moderate Increased metabolism of Lovastatin caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [67]
Darolutamide DMV7YFT Moderate Decreased clearance of Lovastatin due to the transporter inhibition by Darolutamide. Prostate cancer [2C82] [28]
Bicalutamide DMZMSPF Moderate Decreased metabolism of Lovastatin caused by Bicalutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [31]
Ustekinumab DMHTYK3 Moderate Altered metabolism of Lovastatin due to Ustekinumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [28]
Ixekizumab DMXW92T Moderate Altered metabolism of Lovastatin due to Ixekizumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [28]
Bosentan DMIOGBU Moderate Increased metabolism of Lovastatin caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [68]
Tocilizumab DM7J6OR Moderate Altered metabolism of Lovastatin due to Tocilizumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [28]
Canakinumab DM8HLO5 Moderate Altered metabolism of Lovastatin due to Canakinumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [28]
Rilonacept DMGLUQS Moderate Altered metabolism of Lovastatin due to Rilonacept alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [28]
Golimumab DMHZV7X Moderate Altered metabolism of Lovastatin due to Golimumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [28]
Sarilumab DMOGNXY Moderate Altered metabolism of Lovastatin due to Sarilumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [28]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Lovastatin caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [31]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Lovastatin caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [28]
Larotrectinib DM26CQR Moderate Decreased metabolism of Lovastatin caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [31]
Armodafinil DMGB035 Moderate Increased metabolism of Lovastatin caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [25]
LEE011 DMMX75K Moderate Decreased metabolism of Lovastatin caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [31]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Lovastatin and Naltrexone. Substance abuse [6C40] [69]
Fostamatinib DM6AUHV Moderate Decreased clearance of Lovastatin due to the transporter inhibition by Fostamatinib. Thrombocytopenia [3B64] [70]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Lovastatin due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [71]
Brilinta DMBR01X Moderate Decreased metabolism of Lovastatin caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [28]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Lovastatin and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [72]
Tacrolimus DMZ7XNQ Moderate Increased plasma concentrations of Lovastatin and Tacrolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [72]
Amiodarone DMUTEX3 Major Decreased metabolism of Lovastatin caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [73]
⏷ Show the Full List of 125 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
D&C red no. 30 E00456 3000709 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Glyceryl monostearate E00310 24699 Emollient; Emulsifying agent; Emulsion stabilizing agent; Solubilizing agent; Surfactant; Viscosity-controlling agent
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
Acetyltributyl citrate E00127 6505 Plasticizing agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Butylhydroxyanisole E00308 24667 Antimicrobial preservative; Antioxidant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Poloxamer 188 E00645 Not Available Emulsifying agent; Solubilizing agent; Surfactant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium chloride E00077 5234 Diluent; Tonicity agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
⏷ Show the Full List of 25 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Lovastatin 20 mg tablet 20 mg 24 HR Extended Release Oral Tablet Oral
Lovastatin 40 mg tablet 40 mg 24 HR Extended Release Oral Tablet Oral
Lovastatin 60 mg tablet 60 mg 24 HR Extended Release Oral Tablet Oral
Lovastatin 10 mg tablet 10 mg Oral Tablet Oral
Lovastatin 40 mg tablet 40 mg Oral Tablet Oral
Lovastatin 20 mg tablet 20 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Lovastatin FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2739).
3 Clinical pipeline report, company report or official report of CardioPharma Wilmington.
4 BDDCS applied to over 900 drugs
5 Wind S, Schmid U, Freiwald M, Marzin K, Lotz R, Ebner T, Stopfer P, Dallinger C: Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib. Clin Pharmacokinet. 2019 Sep;58(9):1131-1147. doi: 10.1007/s40262-019-00766-0.
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. Neoplasia. 2002 Jul-Aug;4(4):337-46.
8 A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999 Dec 24;274(52):37161-8.
9 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
10 Metabolic interactions with statins. Tidsskr Nor Laegeforen. 2001 Jan 20;121(2):189-93.
11 Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
12 Paraoxonases-1, -2 and -3: what are their functions? Chem Biol Interact. 2016 Nov 25;259(Pt B):51-62.
13 NCI60 cancer cell line panel data and RNAi analysis help identify EAF2 as a modulator of simvastatin and lovastatin response in HCT-116 cells. PLoS One. 2011 Apr 4;6(4):e18306. doi: 10.1371/journal.pone.0018306.
14 Inhibitory effects of clinical reagents having anti-oxidative activity on transforming growth factor-1-induced expression of -smooth muscle actin in human fetal lung fibroblasts. J Toxicol Sci. 2011;36(6):733-40. doi: 10.2131/jts.36.733.
15 Protection against the Neurotoxic Effects of -Amyloid Peptide on Cultured Neuronal Cells by Lovastatin Involves Elevated Expression of 7 Nicotinic Acetylcholine Receptors and Activating Phosphorylation of Protein Kinases. Am J Pathol. 2018 Apr;188(4):1081-1093. doi: 10.1016/j.ajpath.2017.11.020. Epub 2018 Jan 16.
16 Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46.
17 Survivin down-regulation plays a crucial role in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced apoptosis in cancer. J Biol Chem. 2007 Jul 6;282(27):19273-81. doi: 10.1074/jbc.M610350200. Epub 2007 May 1.
18 Statins induce apoptosis in ovarian cancer cells through activation of JNK and enhancement of Bim expression. Cancer Chemother Pharmacol. 2009 May;63(6):997-1005. doi: 10.1007/s00280-008-0830-7. Epub 2008 Sep 3.
19 A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
20 Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44. J Biol Chem. 2011 Apr 1;286(13):11314-27. doi: 10.1074/jbc.M110.193714. Epub 2011 Jan 3.
21 Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
22 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
23 Canadian Pharmacists Association.
24 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
25 Cerner Multum, Inc. "Australian Product Information.".
26 Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
27 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
28 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
29 Multum Information Services, Inc. Expert Review Panel.
30 Holtzman CW, Wiggins BS, Spinler SA "Role of P-glycoprotein in statin drug interactions." Pharmacotherapy 26 (2006): 1601-7. [PMID: 17064205]
31 Agbin NE, Brater DC, Hall SD "Interaction of diltiazem with lovastatin and pravastatin." Clin Pharmacol Ther 61 (1997): 201. [PMID: 9797793]
32 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
33 Ayanian JZ, Fuchs CS, Stone RM "Lovastatin and rhabdomyolysis." Ann Intern Med 109 (1988): 682-3. [PMID: 3421582]
34 Andreou ER, Ledger S "Potential drug interaction between simvastatin and danazol causing rhabdomyolysis." Can J Clin Pharmacol 10 (2003): 172-4. [PMID: 14712320]
35 Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
36 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
37 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
38 Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
39 Alderman CP "Possible interaction between nefazodone and pravastatin." Ann Pharmacother 33 (1999): 871. [PMID: 10466919]
40 He K, Woolf TF, Hollenberg PF "Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486)." J Pharmacol Exp Ther 288 (1999): 791-7. [PMID: 9918590]
41 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
42 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
43 Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
44 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
45 Akram K, Rao S, Parker M "A lesson for everyone in drug-drug interactions." Int J Cardiol 118 (2007): e19-20. [PMID: 17368833]
46 Bogman K, Peyer AK, Torok M, Kusters E, Drewe J "HMG-CoA reductase inhibitors and P-glycoprotein modulation." Br J Pharmacol 132 (2001): 1183-92. [PMID: 11250868]
47 Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
48 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
49 Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
50 Product Information. Rescriptor (delavirdine). Pharmacia and Upjohn, Kalamazoo, MI.
51 Barry M, Mulcahy F, Merry C, Gibbons S, Back D "Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection." Clin Pharmacokinet 36 (1999): 289-304. [PMID: 10320951]
52 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
53 Gerber JG, Rosenkranz SL, Fichtenbaum CJ, et al. "Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study." J Acquir Immune Defic Syndr 39 (2005): 307-12. [PMID: 15980690]
54 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
55 Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
56 Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
57 Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
58 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
59 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
60 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
61 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
62 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
63 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
64 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
65 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
66 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
67 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
68 Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
69 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
70 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
71 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
72 Barshes NR, Goodpastor SE, Goss JA "Sirolimus-atorvastatin drug interaction in the pancreatic islet transplant recipient." Transplantation 76 (2003): 1649-50. [PMID: 14702546]
73 Chouhan UM, Chakrabarti S, Millward LJ "Simvastatin interaction with clarithromycin and amiodarone causing myositis." Ann Pharmacother 39 (2005): 1760-1. [PMID: 16159992]